How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,855 results for

Imiquimod

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Therapeutic Effects of Methanol Extract from Euphorbia kansui Radix on Imiquimod-Induced Psoriasis Full Text available with Trip Pro

Therapeutic Effects of Methanol Extract from Euphorbia kansui Radix on Imiquimod-Induced Psoriasis The roots of Euphorbia kansui, which belong to the family Euphorbiaceae, have been used as a traditional medicine for the treatment of various diseases such as diabetes, ascites, and leukemia. Recently, it was reported that the methylene chloride fraction of E. kansui radix (EKC) regulated the differentiation of Th17 cells and alleviated the symptoms of Th17-related inflammatory bowel disease (...) . Imiquimod (IMQ), a TLR7/8 agonist, has been used to induce psoriasis in a mouse model. In this study, we evaluated the effect of EKC in an IMQ-induced psoriasis model. EKC effectively inhibited the production of interleukin-17A and interferon-γ in vitro. On this basis, EKC was administered to an animal model of psoriasis. Acanthosis and the infiltration of inflammatory cells into the dermis were significantly reduced by EKC. EKC also inhibited the expression of IL-17A, IL-22, IL-23, IL-12, and RAR

2017 Journal of immunology research

102. Acute exacerbation of myasthenia gravis with topical imiquimod use Full Text available with Trip Pro

Acute exacerbation of myasthenia gravis with topical imiquimod use Imiquimod activates the immune system when applied to a local area. We report a patient with a history of well-controlled myasthenia gravis who was prescribed imiquimod for lentigo maligna. Treatment was halted after 2 weeks when the patient reported itching and irritating sensations in his throat, consistent with previous myasthenia exacerbations. The symptoms improved once imiquimod use was discontinued. We advise clinicians (...) to be cautious when prescribing imiquimod to a patient with a history of myasthenia gravis.

2017 Proceedings (Baylor University. Medical Center)

103. The P2X7 receptor is not essential for development of imiquimod-induced psoriasis-like inflammation in mice Full Text available with Trip Pro

The P2X7 receptor is not essential for development of imiquimod-induced psoriasis-like inflammation in mice Psoriasis is a chronic inflammatory skin disorder, characterised by epidermal hyperplasia (acanthosis) and leukocyte infiltration of the skin. Current therapies are inadequate, highlighting the need for new therapeutic targets. The P2X7 receptor is implicated in the pathogenesis of psoriasis. This study investigated the role of P2X7 in imiquimod (IMQ)-induced psoriasis-like inflammation

2017 Purinergic signalling

104. Topical imiquimod for the palliative treatment of recurrent oral squamous cell carcinoma Full Text available with Trip Pro

Topical imiquimod for the palliative treatment of recurrent oral squamous cell carcinoma 28752123 2019 02 26 2352-5126 3 4 2017 Jul JAAD case reports JAAD Case Rep Topical imiquimod for the palliative treatment of recurrent oral squamous cell carcinoma. 329-331 10.1016/j.jdcr.2017.04.008 Wester Annie A Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois. Eyler Jennifer T JT Division of Dermatology, Loyola University Medical Center, Maywood, Illinois. Swan James W JW (...) Division of Dermatology, Loyola University Medical Center, Maywood, Illinois. eng Case Reports 2017 07 18 United States JAAD Case Rep 101665210 2352-5126 CT, computerized tomography OSCC, oral squamous cell carcinoma RMT, retromolar trigone imiquimod oral squamous cell carcinoma palliative care topical therapy 2017 7 29 6 0 2017 7 29 6 0 2017 7 29 6 1 epublish 28752123 10.1016/j.jdcr.2017.04.008 S2352-5126(17)30088-7 PMC5517834 Anticancer Res. 2010 Jul;30(7):2891-6 20683029 Oral Surg Oral Med Oral

2017 JAAD Case Reports

105. Dual Inhibition of PI3K/Akt and mTOR by the Dietary Antioxidant, Delphinidin, Ameliorates Psoriatic Features In Vitro and in an Imiquimod-Induced Psoriasis-Like Disease in Mice Full Text available with Trip Pro

Dual Inhibition of PI3K/Akt and mTOR by the Dietary Antioxidant, Delphinidin, Ameliorates Psoriatic Features In Vitro and in an Imiquimod-Induced Psoriasis-Like Disease in Mice The treatment of psoriasis remains elusive, underscoring the need for identifying novel disease targets and mechanism-based therapeutic approaches. We recently reported that the PI3K/Akt/mTOR pathway that is frequently deregulated in many malignancies is also clinically relevant for psoriasis. We also provided rationale (...) to the PI3K/Akt/mTOR pathway. Surface plasmon resonance and in silico molecular modeling corroborated Del's direct interactions with three PI3Ks (α/c2β/γ), mTOR, and p70S6K. Del treatment of interleukin-22 or TPA-stimulated normal human epidermal keratinocytes (NHEKs) significantly inhibited proliferation, activation of PI3K/Akt/mTOR components, and secretion of proinflammatory cytokines and chemokines. To establish the in vivo relevance of these findings, an imiquimod (IMQ)-induced Balb/c mouse psoriasis

2017 Antioxidants & redox signaling

106. Imiquimod 5% cream for the treatment of large nodular basal cell carcinoma at the medial canthal area Full Text available with Trip Pro

Imiquimod 5% cream for the treatment of large nodular basal cell carcinoma at the medial canthal area Context (Background): Imiquimod (IMQ) 5% cream is an immunomodulatory and antitumorigenic agent, which was used as a topical treatment regimen, who had periocular basal cell carcinoma (BCC).This study aims to present three cases with large BCC at the medial canthal area treated with IMQ 5% cream.IMQ 5% cream was used in three patients with ages 45, 49, and 73 who preferred medical treatment

2017 Indian journal of ophthalmology

107. Vulvar condylomatosis after sex reassignment surgery in a male-to-female transsexual: Complete response to imiquimod cream Full Text available with Trip Pro

Vulvar condylomatosis after sex reassignment surgery in a male-to-female transsexual: Complete response to imiquimod cream The number of patients seeking sex reassignment surgery is increasing. Approximately 1:30,000 adult males and 1: 100,000 adult females seek this procedure. Neovaginal-related disorders after sex reassignment surgery are increasingly more common. Vulvar condylomatosis is the clinical manifestation of HPV 6- and 11 infection in biological women. The same HPV-subtypes (...) are associated with anogenital warts and penile intraepithelial neoplasia in biological men. We aim to present a case of vulvar condylomatosis after sex reassignment surgery in a male-to-female transsexual and its complete response to 5% imiquimod cream.We describe a case of a 19-year-old female transexual who presented one year after male to female sex reassignment surgery by inverted penile skin vaginoplasty with condyloma accuminata of the vulva. The patient had a complete response to imiquimod 5% cream

2017 Gynecologic Oncology Reports

108. Paeonol ameliorates imiquimod-induced psoriasis-like skin lesions in BALB/c mice by inhibiting the maturation and activation of dendritic cells Full Text available with Trip Pro

Paeonol ameliorates imiquimod-induced psoriasis-like skin lesions in BALB/c mice by inhibiting the maturation and activation of dendritic cells Paeonol, an active component derived from the traditional Chinese medicine Cortex Moutan, possesses anti-inflammatory, analgesic, antioxidant and anti-allergic properties. Psoriasis is a chronic, recurrent, inflammatory dermatosis accompanied by excessive activation of Toll‑like receptors (TLRs) in dendritic cells (DCs), which are primarily responsible (...) for initiating an immune response. We investigated the effect of paeonol on inflammation in an imiquimod (IMQ)-induced psoriasis-like mouse model and murine bone marrow-derived dendritic cells (BMDCs) stimulated by R848. Mice were intragastrically administered 100 mg/kg (high), 50 mg/kg (medium) and 25 mg/kg (low) paeonol, respectively. We evaluated inflammation of psori-asis‑like lesions based on histological changes, protein levels of myeloid differentiation factor 88 (MyD88) and TLR8 in skin lesions

2017 International journal of molecular medicine

109. Does Imiquimod Pretreatment Optimize 308-nm excimer laser (UVB) Therapy in Psoriasis Patients? Full Text available with Trip Pro

Does Imiquimod Pretreatment Optimize 308-nm excimer laser (UVB) Therapy in Psoriasis Patients? Psoriasis continues to be a debilitating skin disease affecting 1-3% of the United States population. Although the effectiveness of several current biologic therapies have described this pathology as a IL-23, TNF-a and Th17-mediated disease, less invasive approaches are still in use and in need of refinement. One of these is the usage of narrow band-UVB (NB-UVB) therapy to deplete specifically intra (...) -epidermal CD3+, CD4+ and CD8+ cells to clear psoriatic plaques.In order to improve NB-UVB therapy, we sought to determine whether skin pre-treatment with the TLR7 agonist imiquimod (IMQ) would help increase the efficiency of the former at resolving psoriatic plaques.Eucerin® Original Moisturizing Lotion (topical vehicle) or Aldara® (imiquimod 5% topical cream) were applied for 5 days once daily to a maximum contiguous area of 25 cm2 (5 cm × 5 cm area). Patients were provided with sachets containing 12.5

2017 Photodermatology, photoimmunology & photomedicine

110. Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma

Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03276832 Recruitment Status : Recruiting First Posted : September 8, 2017 Last Update Posted

2017 Clinical Trials

111. Adjuvant Anal Imiquimod Therapy in Anal HPV-lesions: AdAM-trial

Adjuvant Anal Imiquimod Therapy in Anal HPV-lesions: AdAM-trial Adjuvant Anal Imiquimod Therapy in Anal HPV-lesions: AdAM-trial - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Adjuvant Anal Imiquimod (...) Sponsor: Medical University Innsbruck Information provided by (Responsible Party): Irmgard E Kronberger, MD, Medical University Innsbruck Study Details Study Description Go to Brief Summary: AdAM is a prospective, randomized, controlled, double-blinded, monocentric trial in patients receiving surgical therapy due to anal HPV infection. Aim of the study is to evaluate efficacy of combination therapy (surgical therapy + topical Imiquimod-therapy). It is planned to include 200 patients. 100 patients

2017 Clinical Trials

112. Non-thermal atmospheric plasma ameliorates imiquimod-induced psoriasis-like skin inflammation in mice through inhibition of immune responses and up-regulation of PD-L1 expression Full Text available with Trip Pro

Non-thermal atmospheric plasma ameliorates imiquimod-induced psoriasis-like skin inflammation in mice through inhibition of immune responses and up-regulation of PD-L1 expression Plasma medicine is an emerging novel therapeutic field. It has been reported that plasma can kill bacteria, promote wound healing and induce apoptosis of tumor cells. However, the effects of plasma on immune cells and immune related skin diseases have not been well studied. In this study, we demonstrated that non (...) -thermal atmospheric plasma (NTP) treatment could inhibit psoriasis-like skin inflammation in mice. NTP treatment in imiquimod-induced psoriasis-like mouse skin inhibited increases in epithelial cell thickness and expression of pro-inflammatory molecules compared to ones without the NTP treatment. In addition, differentiation of Th17 cells, an important cell type for pathogenesis of psoriasis, was inhibited in the NTP-treated mouse lymph nodes. It was also demonstrated that liquid type plasma (LTP

2017 Scientific reports

113. Intralesional 5-Fluorouracil (5FU), Topical Imiquimod Treatment for SCC

Intralesional 5-Fluorouracil (5FU), Topical Imiquimod Treatment for SCC Intralesional 5-Fluorouracil (5FU), Topical Imiquimod Treatment for SCC - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Intralesional (...) 5-Fluorouracil (5FU), Topical Imiquimod Treatment for SCC The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03370406 Recruitment Status : Recruiting First Posted : December 12, 2017 Last Update Posted : December 24

2017 Clinical Trials

114. Recurrence of lentigo maligna and melanoma in situ after topical treatment with 5% imiquimod: a meta-analysis

Recurrence of lentigo maligna and melanoma in situ after topical treatment with 5% imiquimod: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

115. Topical Challenge With Omiganan and Imiquimod in Healthy Volunteers

Topical Challenge With Omiganan and Imiquimod in Healthy Volunteers Topical Challenge With Omiganan and Imiquimod in Healthy Volunteers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Topical Challenge (...) With Omiganan and Imiquimod in Healthy Volunteers The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03071679 Recruitment Status : Completed First Posted : March 7, 2017 Last Update Posted : May 22, 2017 Sponsor: Cutanea Life Sciences, Inc. Information provided by (Responsible Party): Cutanea Life Sciences, Inc

2017 Clinical Trials

116. Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)

Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3) Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results (...) information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing

2017 Clinical Trials

117. Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia

Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100 (...) ). Please remove one or more studies before adding more. Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03196180

2017 Clinical Trials

118. Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod.

Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod. Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety (...) and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03206138 Recruitment Status : Recruiting First Posted : July 2, 2017 Last Update Posted : July 2, 2017 See

2017 Clinical Trials

119. Randomized Clinical Trial Evaluating the Efficacy of Topical Imiquimod in High Grade Cervical Intraepithelial Lesions

Randomized Clinical Trial Evaluating the Efficacy of Topical Imiquimod in High Grade Cervical Intraepithelial Lesions Randomized Clinical Trial Evaluating the Efficacy of Topical Imiquimod in High Grade Cervical Intraepithelial Lesions - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Randomized Clinical Trial Evaluating the Efficacy of Topical Imiquimod in High Grade Cervical Intraepithelial Lesions The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details

2017 Clinical Trials

120. Anti-psoriatic potential of Solanum xanthocarpum stem in Imiquimod-induced psoriatic mice model. (Abstract)

Anti-psoriatic potential of Solanum xanthocarpum stem in Imiquimod-induced psoriatic mice model. The plant Solanum xanthocarpum Schrad. & Wendl. (Solanaceae) is one of the members of the dashamula (ten roots) in Ayurvedic system of medicine. The stem and fruits are used as an antipyretic, antiasthmatic and is prescribed in skin infections and for relief in burning sensation in the feet accompanied by vesicular eruptions.To scientifically validate the anti-psoriatic potential of Solanum (...) xanthocarpum stem in Imiquimod-induced psoriatic mice model.Ethanolic stems extract of Solanum xanthocarpum (ESX) was first subjected to phytochemical screening and quantification of identified phytoconstituents, which was further standardized with the help of HPTLC using chlorogenic acid as a marker. The extract was then subjected to acute oral toxicity and skin irritability study for determining the safety profile of the extract. Imiquimod-induced psoriatic mouse model was then performed to check

2017 Journal of Ethnopharmacology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>